I have both a purity figure and a content figure, which is why the discrepancy is visible.
I am at the decision point and I would rather think it through than improvise.
I would rather spend money on measurement than on redundancy.
What is the minimum version of this that is still defensible?
The underlying point is that if a lot has visibly segregated — some vials showing different appearance — then sampling the top and bottom of the shipment is worth doing.
Stratified sampling — testing one vial from the top, one from the middle, and one from the bottom of a shipment — is cheap insurance against segregation.
| Δ mass (Da) | Most likely cause | Distinguishing feature |
|---|---|---|
| +1 | Deamidation (Asn or Gln) | New peak, slightly earlier retention |
| −17 | Loss of ammonia | Often with deamidation |
| −18 | Dehydration / succinimide | pH-dependent, reversible |
| +16 | Oxidation (Met, Trp) | Earlier retention, light-related |
| −128 | Missing Gln or Lys | Deletion sequence from synthesis |
| 0 | Isomer: racemisation or scrambling | Same mass, shifted retention |
In practice, the sample size determination requires choosing a confidence level and an acceptable error rate, and the smaller the error rate you want, the larger your sample must be.
Lyophilised peptide homogeneity studies show that vial-to-vial variation is usually small but occasionally large, depending on the distribution in the freeze-dryer.
I would treat a "complies with" statement without sampling details as a claim rather than as evidence.
Assume segregation is possible, and design your sampling to catch it if it exists.
HPLC purity, identity confirmation and quantified content on the vial you actually hold. Reports arrive with the chromatogram attached, not just a number.
Submit a sampleFounded 1998. ISO 9001 and cGMP certified, 1,500+ staff and 200+ patents. The synthesis house behind a great many of the vials that get sent out for testing - batch-specific documentation with every order.
Visit GL BiochemA certificate that reports one test result on one vial extrapolates to claim that all two hundred vials in the lot are identical, which is an assumption worth questioning.
If you have reason to suspect inhomogeneity — different appearance in different vials, or a long or warm shipment — testing more vials is the diagnostic move.
Testing a vial that has been open in the lab for three months is testing aged material, not the fresh lot, and the result should be explicitly noted as a retest.
Published data on lot homogeneity from manufacturers who sample multiple vials consistently find variation below the published specifications, suggesting the sampling plans work.
If testing multiple vials, state how many you tested and why you chose those vials.
Sampling plans exist precisely because testing everything is expensive, and they define the statistical relationship between sample size and lot-wide inference.
The statistical foundation here is well-established, which is why sampling plans from decades ago are still valid.
Published segregation failures show that even modern automated processes sometimes produce lots with measurable vial-to-vial variation.
Sampling plans for pharmaceutical manufacturing are defined in ISO 2859 and ANSI Z1.4, and they are based on statistical sampling theory.
The practical summary: a lot number without a sampling statement is a lot number without meaning.
More usefully, the single most misleading statement on a research-grade certificate is a lot number with no statement of how many vials from that lot were tested.
For a quantitative result like content, the acceptable range determines how many vials you need to test to establish the lot complies.
Lyophilised peptide homogeneity studies show that vial-to-vial variation is usually small but occasionally large, depending on the distribution in the freeze-dryer.
One qualification: testing more vials gives better confidence, but at some point the cost outweighs the benefit.
Assume segregation is possible, and design your sampling to catch it if it exists.
Start from the question: how many vials from this lot do I need to test to claim that the lot meets specification, and the answer depends on both the lot size and the acceptable risk.
If the lot was manufactured in multiple batches, testing vials from each batch separately establishes whether batch-to-batch variation is acceptable.
Worth noting that thermal excursions during shipping affect different vials differently, so the lot may not be homogeneous even if it left the factory that way.
If testing multiple vials, state how many you tested and why you chose those vials.
Ask PeptideStack is a static archive. Posting is closed, but the norms are worth stating: answer the question that was asked, show your working, cite the trial or the certificate, and say plainly where the evidence runs out.